⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 12, 2024Expert Opinion on PharmacotherapyOpen Access

What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?

Megan Metzger John Mascarenhas

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

KEYWORDS: Polycythemia verahydroxyurea resistanceinterferonruxolitinibhepcidin mimetichistone deacetylase inhibitorLSD1 inhibitor

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Metzger et al. (2024) studied this question.

synapsesocial.com/papers/6a1a8c249fa30811a0b8c495 https://doi.org/10.1080/14656566.2024.2396029

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersOriginal Research · 2005 · 3,592 citations
2Targeted deep sequencing in polycythemia vera and essential thrombocythemiaOriginal Research · 2016 · 313 citations
3Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia veraPrognostic Study · 2020 · 233 citations
4Cardiovascular Events and Intensity of Treatment in Polycythemia VeraCohort Study · 2012 · 871 citations
5A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched studyCohort Study · 2017 · 87 citations
6Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraEarly-Phase Clinical Trial · 2008 · 582 citations
7Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaEarly-Phase Clinical Trial · 2019 · 178 citations
8Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatmentCohort Study · 2023 · 83 citations
9An update on pharmacotherapies and emerging therapeutic approaches for geographic atrophyExpert Opinion on Pharmacotherapy · 2026
10Current perspectives on the pharmacotherapeutic management of Anaplastic thyroid cancerExpert Opinion on Pharmacotherapy · 2026

More from Expert Opinion on Pharmacotherapy

More from Icahn School of Medicine at Mount Sinai